Cargando…
Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities
Mesenchymal stromal cells (MSCs) are a major component of the tumour microenvironment. A plethora of elegant studies focusing on tumour-derived MSCs have shown that they, unlike normal MSCs in other tissue, exhibit a strong ability to promote tumour progression. However, the mechanisms underlying th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116561/ https://www.ncbi.nlm.nih.gov/pubmed/27132512 http://dx.doi.org/10.1038/onc.2016.131 |
_version_ | 1782468682209820672 |
---|---|
author | Lin, L Y Du, L M Cao, K Huang, Y Yu, P F Zhang, L Y Li, F Y Wang, Y Shi, Y F |
author_facet | Lin, L Y Du, L M Cao, K Huang, Y Yu, P F Zhang, L Y Li, F Y Wang, Y Shi, Y F |
author_sort | Lin, L Y |
collection | PubMed |
description | Mesenchymal stromal cells (MSCs) are a major component of the tumour microenvironment. A plethora of elegant studies focusing on tumour-derived MSCs have shown that they, unlike normal MSCs in other tissue, exhibit a strong ability to promote tumour progression. However, the mechanisms underlying the conversion of normal MSCs into tumour-associated MSCs are unknown. We report here a critical role of tumour cell-derived exosomes in endowing bone marrow-derived MSCs (BM-MSCs) with a tumour-favourable phenotype. Tumour cell-derived exosomes affected neither the growth factor production nor the immunosuppressive property of MSCs; rather, they endowed MSCs with a strong ability to promote macrophage infiltration into B16-F0 melanoma or EL-4 lymphoma. Ablation of macrophages by clodronate liposome administration reversed the tumour-promoting effect of MSCs educated by tumour cell-derived exosomes (TE-MSCs) on the tumour growth. By comparing the chemokine profile of BM-MSCs with that of TE-MSCs, we found that TE-MSCs produced a large amount of CCR2 ligands, CCL2 and CCL7, which are responsible for macrophage recruitment. CCR2-specific inhibitor was found to block the tumour-promoting effect of TE-MSCs. Thus, our investigations demonstrated that tumour cell-derived exosomes confer BM-MSCs the ability to enhance tumour growth. Therefore, we uncovered a novel mechanism underlying the conversion of normal MSCs to tumour-associated MSCs. |
format | Online Article Text |
id | pubmed-5116561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51165612016-12-16 Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities Lin, L Y Du, L M Cao, K Huang, Y Yu, P F Zhang, L Y Li, F Y Wang, Y Shi, Y F Oncogene Short Communication Mesenchymal stromal cells (MSCs) are a major component of the tumour microenvironment. A plethora of elegant studies focusing on tumour-derived MSCs have shown that they, unlike normal MSCs in other tissue, exhibit a strong ability to promote tumour progression. However, the mechanisms underlying the conversion of normal MSCs into tumour-associated MSCs are unknown. We report here a critical role of tumour cell-derived exosomes in endowing bone marrow-derived MSCs (BM-MSCs) with a tumour-favourable phenotype. Tumour cell-derived exosomes affected neither the growth factor production nor the immunosuppressive property of MSCs; rather, they endowed MSCs with a strong ability to promote macrophage infiltration into B16-F0 melanoma or EL-4 lymphoma. Ablation of macrophages by clodronate liposome administration reversed the tumour-promoting effect of MSCs educated by tumour cell-derived exosomes (TE-MSCs) on the tumour growth. By comparing the chemokine profile of BM-MSCs with that of TE-MSCs, we found that TE-MSCs produced a large amount of CCR2 ligands, CCL2 and CCL7, which are responsible for macrophage recruitment. CCR2-specific inhibitor was found to block the tumour-promoting effect of TE-MSCs. Thus, our investigations demonstrated that tumour cell-derived exosomes confer BM-MSCs the ability to enhance tumour growth. Therefore, we uncovered a novel mechanism underlying the conversion of normal MSCs to tumour-associated MSCs. Nature Publishing Group 2016-11-17 2016-05-02 /pmc/articles/PMC5116561/ /pubmed/27132512 http://dx.doi.org/10.1038/onc.2016.131 Text en Copyright © 2016 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Short Communication Lin, L Y Du, L M Cao, K Huang, Y Yu, P F Zhang, L Y Li, F Y Wang, Y Shi, Y F Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities |
title | Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities |
title_full | Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities |
title_fullStr | Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities |
title_full_unstemmed | Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities |
title_short | Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities |
title_sort | tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116561/ https://www.ncbi.nlm.nih.gov/pubmed/27132512 http://dx.doi.org/10.1038/onc.2016.131 |
work_keys_str_mv | AT linly tumourcellderivedexosomesendowmesenchymalstromalcellswithtumourpromotioncapabilities AT dulm tumourcellderivedexosomesendowmesenchymalstromalcellswithtumourpromotioncapabilities AT caok tumourcellderivedexosomesendowmesenchymalstromalcellswithtumourpromotioncapabilities AT huangy tumourcellderivedexosomesendowmesenchymalstromalcellswithtumourpromotioncapabilities AT yupf tumourcellderivedexosomesendowmesenchymalstromalcellswithtumourpromotioncapabilities AT zhangly tumourcellderivedexosomesendowmesenchymalstromalcellswithtumourpromotioncapabilities AT lify tumourcellderivedexosomesendowmesenchymalstromalcellswithtumourpromotioncapabilities AT wangy tumourcellderivedexosomesendowmesenchymalstromalcellswithtumourpromotioncapabilities AT shiyf tumourcellderivedexosomesendowmesenchymalstromalcellswithtumourpromotioncapabilities |